Immunohistochemical profile of carcinoma breast and its association with clinicopathological features: a single institutional experience
DOI:
https://doi.org/10.18203/2349-2902.isj20220942Keywords:
Breast cancer, Hormone receptor, HER 2neu, IHCAbstract
Background: Breast cancer is a systemic disease which has different biological subtypes with vast natural history, clinical presentation, various pathological types and molecular features which has impact on prognostic profile and outcome. Present study aims to evaluate correlation of receptor status (ER, PR and HER 2neu) with other tumor characteristics.
Methods: The present study was a prospective observational study of 50 breast cancer patients and was conducted from January 2020 to June 2021 in surgical unit of the department of general surgery at MDM hospital attached with Dr. S. N. medical college, Jodhpur, Rajasthan.
Results: Most common age group was 41-50 years in 38% cases. Majority of patients were females (49, 98%). The 88% cases had invasive duct carcinoma. ER, PR and HER 2neu positivity had statistically significant correlation with age (p<0.0001), histological grade (p<0.0001) and tumor size (p=0.04). HER 2neu had statistically significant negative correlation with ER and PR (p<0.05).
Conclusions: Immunohistochemistry (IHC) markers (ER, PR, HER 2neu) are positively correlated with increasing age, tumor size, tumor grade and positive axillary lymph nodes, also there is statistically significant correlation between HER 2neu overexpression and hormone receptor (ER, PR) negativity in study population.
References
Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med insights Pathol. 2015;8:CPath-S31563.
Rajpal S, Kumar A, Joe W. Economic burden of cancer in India: Evidence from cross sectional nationally representative household survey-2014. PLoS ONE .2018;13(2):1-17.
Perou CM, Sørlie T, Eisen MB, Van De Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-52.
Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J National Cancer Institute. 2007;99:1152-61.
Rampaul RS, Pinder SE, Elaston CW, Ellis IO. Prognostic and predictive factors in primary breast cancer and their role in patient management; the Nottingham breast team. Eur J Surg Oncol. 2001;27:229-38.
Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ et al. The decrease in breast-cancer incidence in 2003 in the United States. N Eng J Med. 2007;356:1670-4.
Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334-56.
McGuire WL, Clark GM. The prognostic role of progesterone receptors in human breast cancer. In Seminars in oncology. 1983;10(4):2-6.
Hung MC, Lau YK. Basic science of HER-2/neu: a review. In Seminars in oncology. 1999;4(12):51-9.
Takalkar UV, Asegaonkar SB, Kulkarni U, Kodlikeri PR, Kulkarni U, Saraf M, Advani S. Clinicopathological profile of breast cancer patients at a tertiary care hospital in Marathwada region of Westen India. Asian Pacific J Cancer Prev. 2016;17(4):2195-8.
Sandhu DS, Sandhu S, Karwasra RK, Marwah S. Profile of breast cancer patients at a tertiary care hospital in north India. Indian J Cancer. 2010;47:16-22.
Pervin MM, Nath HD, Bahar MM, Alam A, Bhowmik J. Study on clinical presentation of breast carcinoma of 50 cases. ChattagramMaa-O-Shishu Hospital Med College J. 2014;13(2):8-11.
Acharya SC, Jha AK, Manandhar T. Clinical Profile of Patients Presenting with Breast Cancer in Nepal. Kathmandu Uni Med J. 2012;39(3):3-7.
Kumar A, Singh D, Gupta ML. Correlation of morphological profile and receptor status in breast carcinoma: An institutional study in tertiary care hospital. J Med Sci Clin Res. 2020;8(1):545-9.
Taucher S, Rudas M, Mader RM. Do we need HER2/neu testing for all patients with primary breast carcinoma? Cancer. 2003;98:2547-53.
Mahalakshmi P, Krishnaswamy B, Gopalakrishnan KR, Dhanalakshmi M, Shyamala E. A Clinicopathological Evaluation of Breast Carcinoma in a Rural Tertiary Care Hospital. J Med Sci Clin Res. 2020;8(11):44-8.
Shoeb MFR, Pinate AR, Shingade PP. Risk factors and clinical presentations of breast cancer patients: a hospital based study. Inte Surg J. 2017;4:645-9.
Stead LA, Lash TL, Sobieraj JE. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res. 2009;11:R18.
Naeem M, Nasir A, Aman Z, Ahmad T, Samad A. Frequency of Her-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med College Abbottabad. 2008;20(3):23-6.
Kohler RE, Moses A, Krysiak R, Liomba NG, Gopal S. Pathologically confirmed breast cancer in Malawi: a descriptive study: Clinical profile of breast cancer. Malawi Med J. 2015;27(1):10-2.
Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev. 2011;12(3):625-9.
Vedashree MK, Rajalakshmi V. Clinico-pathological study of breast carcinoma with correlation to hormone receptor status & HER2/neu. Indian J Pathol Oncol. 2016;3(4):690-5.
Munjal K, Ambaye A, Evans MF. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in Infiltrative Breast Carcinomas in Indian Patients. Asian Pacific J Cancer Prev. 2009;10:773-8.
Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol. 2005;123,541-6.
Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V et al. Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is? Indian J Pathol Microbiol. 2009;52(2):171.
Suvarchala SB, Nageswararao R. Carcinoma breast-histopathological and hormone receptors correlation. J Biosci Tech. 2011;2(4):340-8.
Azizun-Nisa BY, Raza F, Kayani N. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pacific J Cancer Prev. 2008;9(4):553-6.
Saleh F, Abdeen S. Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinogenesis. 2007;6:12.
Fatima S, Faridi N, Gill S. Breast cancer: steroid receptors and other prognostic indicators. Journal of the College of Physicians and Surgeons-Pakistan: JCPSP. 2005;15(4):230-3.
Bhaskar S, Rastogi K, Gupta S, Jindal A, Bhatnagar AR, Jain S. A study of hormone receptor status in breast carcinoma and use of HER2-targeted therapy in a tertiary care center of India. Indian J Med Paediatr Oncol. 2019;40(S 01):S54-60.
Almasri NM, Al Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res. 2005;7:R598-604.
Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. Anticancer Res. 2007;21(4):673-8.
Tokatli F, Altaner S, Uzal C, Ture M, Kocak Z, Uygun K et al. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients. Exp Oncol. 2005;27:145-9.
